Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Pichler, M.
Best of ASCO 2022-bladder cancer
MEMO-MAG EUR MED ONC. 2022;
Doi: 10.1007/s12254-022-00847-0
Web of Science
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Pichler Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Although no game-changing studies in bladder cancer were presented this year at ASCO, we saw a series of interesting data including follow-up updates, exploratory analyses and promising results of phase I/II trials. An up-date analysis of the JAVELIN 100 Bladder study indicated a benefit of avelumab maintenance treatment irrespective of the response to platin-based first-line treatment and administration of second-line treatment. A new HER2-directed antibody drug conjugate, disitamab vedotin, showed promising results with high-response rates in HER2 high and low bladder cancer. Longer follow-up data confirmed the significant benefit of enfortumab-vedotin in the third-line treatment setting.
- Find related publications in this database (Keywords)
- Bladder cancer
- Avelumab
- Enfortumab
- HER2